Using State Space Exploration to Determine How Gene Regulatory Networks Constrain Mutation Order in Cancer Evolution

  • Matthew A. Clarke
  • Steven Woodhouse
  • Nir Piterman
  • Benjamin A. Hall
  • Jasmin FisherEmail author
Part of the Computational Biology book series (COBO, volume 30)


Cancer develops via the progressive accumulation of somatic mutations, which subvert the normal operation of the gene regulatory network of the cell. However, little is known about the order in which mutations are acquired in successful clones. A particular sequence of mutations may confer an early selective advantage to a clone by increasing survival or proliferation, or lead to negative selection by triggering cell death. The space of allowed sequences of mutations is therefore constrained by the gene regulatory network. Here, we introduce a methodology for the systematic exploration of the effect of every possible sequence of oncogenic mutations in a cancer cell modelled as a qualitative network. Our method uses attractor identification using binary decision diagrams and can be applied to both synchronous and asynchronous systems. We demonstrate our method using a recently developed model of ER-negative breast cancer. We show that there are differing levels of constraint in the order of mutations for different combinations of oncogenes, and that the effects of ErbB2/HER2 over-expression depend on the preceding mutations.


  1. 1.
    Ahmed Z, Benque D, Berezin S, Dahl ACE, Fisher J, Hall BA, Ishtiaq S, Nanavati J, Piterman N, Riechert M, Skoblov N (2017) Bringing LTL model checking to biologists. In: Bouajjani A, Monniaux D (eds) Verification, model checking, and abstract interpretation. Springer International Publishing, Cham, pp 1–13. Scholar
  2. 2.
    Arends JW (2000) Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 190(4):412–416. 412::AID-PATH533 3.0.CO;2-P
  3. 3.
    Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP (2006) C-Myc amplifications in primary breast carcinomas and their local recurrences. J Clinic Pathol 59(4):424–428. Scholar
  4. 4.
    Autier P, Boniol M, La Vecchia C, LaVecchia C, Vatten L, Gavin A, Héry C, Heanue M (2010) Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ (Clinical research ed) 341:c3620. Scholar
  5. 5.
    Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA (2013) Punctuated evolution of prostate cancer genomes. Cell 153(3):666–677. Scholar
  6. 6.
    Basanta D, Gatenby RA, Anderson ARA (2012) Exploiting evolution to treat drug resistance: combination therapy and the double bind. Molecu Pharmac 9(4):914–921. Scholar
  7. 7.
    Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L (1998) p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273(20):11995–8CrossRefGoogle Scholar
  8. 8.
    Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA, Vogelstein B, Nowak MA (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2:e00747,
  9. 9.
    Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6(6):229. Scholar
  10. 10.
    van den Brink GR, Offerhaus GJ (2007) The morphogenetic code and colon cancer development. Cancer Cell 11(2):109–117. Scholar
  11. 11.
    Bryant RE (1986) Graph-based algorithms for boolean function manipulation. IEEE Trans Comput 100(8):677–691. Scholar
  12. 12.
    Casás-Selves M, DeGregori J (2011) How cancer shapes evolution and how evolution shapes cancer. Evolut Educat Outreach 4(4):624–634., NIHMS150003Google Scholar
  13. 13.
    Chen Y, Olopade OI (2008) MYC in breast tumor progression. Exp Rev Anticancer Ther 8(10):1689–1698. Scholar
  14. 14.
    Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, Greider CW, DePinho RA (1999) P53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97(4):527–538. Scholar
  15. 15.
    Chong CR, Jänne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389–400., NIHMS150003CrossRefGoogle Scholar
  16. 16.
    Chuang R, Hall BA, Benque D, Cook B, Ishtiaq S, Piterman N, Taylor A, Vardi M, Koschmieder S, Gottgens B, Fisher J (2015) Drug target optimization in chronic myeloid leukemia using innovative computational platform. Scientif Rep 5:8190. Scholar
  17. 17.
    Claessen K, Fisher J, Ishtiaq S, Piterman N, Wang Q (2013) Model-checking signal transduction networks through decreasing reachability sets. In: Computer aided verification. Springer, pp 85–100Google Scholar
  18. 18.
    Cook B, Fisher J, Krepska E, Piterman N (2011) Proving stabilization of biological systems. VMCAI, Springer 11:134–149. Scholar
  19. 19.
    Corzo C, Corominas JM, Tusquets I, Salido M, Bellet M, Fabregat X, Serrano S, Solé F (2006) The myc oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genet Cytogenet 165(2):151–156 Scholar
  20. 20.
    Crasta K, Ganem NJ, Dagher R, Lantermann AB, Ivanova EV, Pan Y, Nezi L, Protopopov A, Chowdhury D, Pellman D (2012) DNA breaks and chromosome pulverization from errors in mitosis. Nature 482(7383):53–58. Scholar
  21. 21.
    Cui Y, Guo G (2016) Immunomodulatory function of the tumor suppressor p53 in host immune response and the tumor microenvironment. Int J Mol Sci 17(11). Scholar
  22. 22.
    D’Antonio M, Tamayo P, Mesirov JP, Frazer KA (2016) Kataegis expression signature in breast cancer is associated with late onset, better prognosis, and higher HER2 levels. Cell Rep 16(3):672–683. Scholar
  23. 23.
    Davis A, Gao R (1867) Navin N (2017) Tumor evolution: linear, branching, neutral or punctuated? Biochimica et Biophysica Acta Rev Cancer 2:151–161. Scholar
  24. 24.
    Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382):506–510. Scholar
  25. 25.
    Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69(1):119–28CrossRefGoogle Scholar
  26. 26.
    Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61(5):759–767. Scholar
  27. 27.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386, arXiv:1011.1669v3CrossRefGoogle Scholar
  28. 28.
    Flanagan L, Van Weelden K, Ammerman C, Ethier SP, Welsh J (1999) SUM-159PT cells: a novel estrogen independent human breast cancer model system. Breast cancer research and treatment 58(3):193–204CrossRefGoogle Scholar
  29. 29.
    Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, Tsai PC, Casasent A, Waters J, Zhang H, Meric-Bernstam F, Michor F, Navin NE (2016) Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet 48(10):1119–30., 15334406CrossRefGoogle Scholar
  30. 30.
    Garg A, Di Cara A, Xenarios I, Mendoza L, De Micheli G (2008) Synchronous versus asynchronous modeling of gene regulatory networks. Bioinformatics 24(17):1917–1925. Scholar
  31. 31.
    Gray JW (2003) Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 4(1):4–6. Scholar
  32. 32.
    Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481(7381):306–13. Scholar
  33. 33.
    Greenman CD, Pleasance ED, Newman S, Yang F, Fu B, Nik-Zainal S, Jones D, Lau KW, Carter N, Edwards PA, Futreal PA, Stratton MR, Campbell PJ (2012) Estimation of rearrangement phylogeny for cancer genomes. Genom Res 22(2):346–361. Scholar
  34. 34.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646–674., 0208024CrossRefGoogle Scholar
  35. 35.
    Hollestelle A, Nagel JHA, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TLM, De Leeuw BHCGM, Zwarthoff EC, Teunisse A, Van Der Spek PJ, Klijn JGM, Dinjens WNM, Ethier SP, Clevers H, Jochemsen AG, Den Bakker MA, Foekens JA, Martens JWM, Schutte M (2010) Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treatm 121(1):53–64. Scholar
  36. 36.
    Holliday DL, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast cancer research : BCR 13:215. Scholar
  37. 37.
    Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model for pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 6(8):2969–72Google Scholar
  38. 38.
    Hurvitz S, Mead M (2015) Triple-negative breast cancer. Current Opinion in Obstetrics and Gynecology p 1,
  39. 39.
    Independent UK Panel on Breast Cancer Screening (2012) The benefits and harms of breast cancer screening: an independent review. Lancet (London, England) 380(9855):1778–86. Scholar
  40. 40.
    Knuth DE (2009) The art of computer programming: bitwise tricks & techniques; Binary Decision Diagrams, vol 4, Fascicle 1. Addison-WesleyGoogle Scholar
  41. 41.
    Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J (1997) Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57(8):1597–604Google Scholar
  42. 42.
    Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA (1986) Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts. Mol Cell Biol 6(6):1917–1925CrossRefGoogle Scholar
  43. 43.
    Lasfargues EY, Ozzello L (1958) Cultivation of human breast carcinomas. J Nat Cancer Institute 21(6):1131–47Google Scholar
  44. 44.
    Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38(4):468–73. Scholar
  45. 45.
    Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM, Stebbings L, Menzies A, Widaa S, Stratton MR, Jones PH, Campbell PJ (2015) High burden and pervasive positive selection of somatic mutations in normal human skin (Supplement). Science 348(6237):880–886. Scholar
  46. 46.
    Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown-Swigart L, Johnson L, Evan GI (2008) Distinct thresholds govern Myc’s biological output in vivo. Cancer cell 14(6):447–57. Scholar
  47. 47.
    Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, Teague JW, Martin S, Jönsson G, Mariani O, Boyault S, Miron P, Fatima A, Langerød A, Aparicio SAJR, Tutt A, Sieuwerts AM, Borg Å, Thomas G, Salomon AV, Richardson AL, Børresen-Dale AL, Futreal PA, Stratton MR, Campbell PJ, Breast Cancer Working Group of the International Cancer Genome Consortium (2012) The life history of 21 breast cancers. Cell 149(5):994–1007. Scholar
  48. 48.
    Notta F, Chan-Seng-Yue M, Lemire M, Li Y, Wilson GW, Connor AA, Denroche RE, Liang SB, Brown AM, Kim JC, Wang T, Simpson JT, Beck T, Borgida A, Buchner N, Chadwick D, Hafezi-Bakhtiari S, Dick JE, Heisler L, Hollingsworth MA, Ibrahimov E, Jang GH, Johns J, Jorgensen LG, Law C, Ludkovski O, Lungu I, Ng K, Pasternack D, Petersen GM, Shlush LI, Timms L, Tsao MS, Wilson JM, Yung CK, Zogopoulos G, Bartlett JM, Alexandrov LB, Real FX, Cleary SP, Roehrl MH, McPherson JD, Stein LD, Hudson TJ, Campbell PJ, Gallinger S (2016) A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538(7625):378–382., NIHMS150003CrossRefGoogle Scholar
  49. 49.
    Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR (2015) Effect of Mutation Order on Myeloproliferative Neoplasms. The New England journal of medicine 372(7):601–612., N Engl J Med 2011;365:981-92. CopyrightCrossRefGoogle Scholar
  50. 50.
    Robanus-Maandag EC, Bosch CAJ, Kristel PM, Hart AAM, Faneyte IF, Nederlof PM, Peterse JL, van de Vijver MJ (2003) Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 201(1):75–82. Scholar
  51. 51.
    Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB, Behjati S, Mitchell TJ, Grossmann S, Lightfoot H, Egan DA, Pronk A, Smakman N, van Gorp J, Anderson E, Gamble SJ, Alder C, van de Wetering M, Campbell PJ, Stratton MR, Clevers H (2018) Intra-tumour diversification in colorectal cancer at the single-cell level. Nature. Scholar
  52. 52.
    Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, Sundsbak R, Shapiro V, Muders MH, Smyrk T, Couch FJ (2011) Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology 140(4):1303–1313.e1–3, Scholar
  53. 53.
    Sánchez-Rivera FJ, Jacks T (2015) Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 15(7):387–95. Scholar
  54. 54.
    Schaub MA, Henzinger TA, Fisher J (2007) Qualitative networks: a symbolic approach to analyze biological signaling networks. BMC Syst Biol 1:4. Scholar
  55. 55.
    Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265):809–813. Scholar
  56. 56.
    Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SWG, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey J, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486(7403):395–399., NIHMS150003CrossRefGoogle Scholar
  57. 57.
    Shavit Y, Yordanov B, Dunn SJ, Wintersteiger CM, Hamadi Y, Kugler H (2015) Switching Gene Regulatory Networks. In: International conference on information processing in cells and tissues. Springer, Cham, pp 131–144, Scholar
  58. 58.
    Silverbush D, Grosskurth S, Wang D, Powell F, Gottgens B, Dry J, Fisher J (2017) Cell-specific computational modeling of the PIM pathway in acute myeloid leukemia. Cancer Res 77(4):827–838. Scholar
  59. 59.
    Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR (2010) Germline Brca2 heterozygosity promotes KrasG12D -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18(5):499–509. Scholar
  60. 60.
    Sotiriou C, Neo SYY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Nat Acad Sci USA 100(18):10393–10398. Scholar
  61. 61.
    Sottoriva A, Kang H, Ma Z, Graham TA, Salomon MP, Zhao J, Marjoram P, Siegmund K, Press MF, Shibata D, Curtis C (2015) A big bang model of human colorectal tumor growth. Nat Genet 47(3):209–216., 15334406CrossRefGoogle Scholar
  62. 62.
    Sprouffske K, Pepper JW, Maley CC (2011) Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prevent Res 4(7):1135–1144. Scholar
  63. 63.
    Sun QY, Ding LW, Tan KT, Chien W, Mayakonda A, Lin DC, Loh XY, Xiao JF, Meggendorfer M, Alpermann T, Garg M, Lim SL, Madan V, Hattori N, Nagata Y, Miyano S, Yeoh AEJ, Hou HA, Jiang YY, Takao S, Liu LZ, Tan SZ, Lill M, Hayashi M, Kinoshita A, Kantarjian HM, Kornblau SM, Ogawa S, Haferlach T, Yang H, Koeffler HP (2017) Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD). Leukemia 31(1):1–10. Scholar
  64. 64.
    Tabassum DP, Polyak K (2015) Tumorigenesis: it takes a village. Nat Rev Cancer 15(8):473–483. Scholar
  65. 65.
    Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–76. Scholar
  66. 66.
    Turajlic S, McGranahan N (1855) Swanton C (2015) Inferring mutational timing and reconstructing tumour evolutionary histories. Biochimica et Biophysica Acta Rev Cancer 2:264–275. Scholar
  67. 67.
    Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F, Meric-Bernstam F, Navin NE (2014) Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 512(7513):155–160., NIHMS150003CrossRefGoogle Scholar
  68. 68.
    Wu X, Sun L, Wang X, Su P, Li Z, Zhang C, Wang Y, Gao P, Ma R (2016) Breast cancer invasion and metastasis by mPR\(\alpha \) through the PI3K/Akt signaling pathway. Pathol Oncol Res POR 22(3):471–6. Scholar
  69. 69.
    Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, Aas T, Alexandrov LB, Larsimont D, Davies H, Li Y, Ju YS, Ramakrishna M, Haugland HK, Lilleng PK, Nik-Zainal S, McLaren S, Butler A, Martin S, Glodzik D, Menzies A, Raine K, Hinton J, Jones D, Mudie LJ, Jiang B, Vincent D, Greene-Colozzi A, Adnet PY, Fatima A, Maetens M, Ignatiadis M, Stratton MR, Sotiriou C, Richardson AL, Lønning PE, Wedge DC, Campbell PJ (2015) Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21(7):751–759. arXiv:1408.1149CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Matthew A. Clarke
    • 1
  • Steven Woodhouse
    • 2
  • Nir Piterman
    • 3
  • Benjamin A. Hall
    • 4
  • Jasmin Fisher
    • 1
    • 5
    Email author
  1. 1.Department of BiochemistryUniversity of CambridgeCambridgeUK
  2. 2.Department of GeneticsUniversity of PennsylvaniaPhiladelphiaUSA
  3. 3.Department of Computer ScienceUniversity of LeicesterLeicesterUK
  4. 4.MRC Cancer UnitUniversity of CambridgeCambridgeUK
  5. 5.Microsoft Research CambridgeCambridgeUK

Personalised recommendations